Log in to your Inderes Free account to see all free content on this page.
Pharma Equity Group
0.158
DKK
+0.32 %
PEG
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
13 following
+0.32%
-25%
-36.75%
-32.11%
-63.37%
-67.46%
-50%
-84.48%
-99.39%
pharmaequitygroup.com/investors
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
PEG
Daily low / high price
0.156 / 0.162
DKK
Market cap
193.34M DKK
Turnover
6.6K DKK
Volume
41K
ShowingAll content types
Consolidated Interim report 1 January – 30 September 2024
Pharma Equity Group (One-pager): Capital position strenghtened
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.
Major shareholder announcement - Pharma Equity Group A/S
Managers’ transactions
Pharma Equity Group announces successful completion of directed issue of new shares
Pharma Equity Group: Directed issue with premium to closing price.
Pharma Equity Group announces issuance of new shares in a direct issue
Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights
Consolidated Interim Report 1 January – 30 June 2024
The Board of Directors' decision to issue convertible loans
Major shareholder announcement - Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S
HCA Capital: Wrap up from 2024 Life Science seminar
Life Science seminar 2024
Results of extraordinary general meeting in Pharma Equity Group A/S